Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...

Ministero della Salute
Bibliografia
Artifon EL, Couto D Jr, Sakai O, da Silveira EB.
Prospective evaluation of EUS versus CT scan for staging
of ampullary cancer. Gastrointest Endosc 2009;
70: 290-6
Balzano G, Zerbi A, Capretti G, et al. Effect of hospital
volume on outcome of pancreaticoduodenectomy in
Italy. Br J Surg 2008; 95: 357-62
Banu E, Banu A, Fodor A, et al. Meta-analysis of randomised
trials comparing gemcitabine-based doublets
versus gemcitabine alone in patients with advanced
and metastatic pancreatic cancer. Drugs Aging 2007;
24: 865-79
Bettini R, Mantovani W, Boninsegna L, et al. Primary
tumour resection in metastatic non-functioning pancreatic
endocrine carcinomas. Dig Liver Dis 2009; 41:
49-55
Boz G, De Paoli A, Innocente R, et al. Radiotherapy
and chemotherapy in pancreatic cancer. Topical issues
and future perspectives. JOP 2006; 7: 122-30
Boz G, De Paoli A, Innocente R, et al. Radiotherapy
and continuous infusion 5-fluorouracil in patients
with nonresectable pancreatic carcinoma. Int J Radiat
Oncol Biol Phys 2001; 51: 736-40
Bria E, Milella M, Gelibter A, et al. Gemcitabinebased
combinations for inoperable pancreatic cancer:
have we made real progress A meta-analysis of 20
phase 3 trials. Cancer 2007; 110: 525-33
Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements
in survival and clinical benefit with gemcitabina
as first-line therapy for patients with advanced pancreas
cancer. A randomized trial. J Clin Oncol 1997; 15:
2403-13
Butturini G, Crippa S, Bassi C, et al. The role of laparoscopy
in advanced pancreatic cancer diagnosis. Dig
Surg 2007; 24: 33-7
Cantore M, Serio G, Pederzoli P, et al. Adjuvant intra-arterial
5-fluorouracil, leucovorin, epirubicin and
carboplatin with or without systemic gemcitabina after
curative resection for pancreatic adenocarcinoma. Cancer
Chemother Pharmacol 2006; 58: 504-8
Chang DK, Johns AL, Merrett ND, et al. Margin
clearance and outcome in resected pancreatic cancer.
J Clin Oncol 2009; 27: 2855-62
DeLellis RA, Loyd RV, Heitz PU, Eng C (eds.). World
Health Organization Classification of Tumour. Pathology
and Genetics of the Digestive System. Lyon: IARC
press, 2000
Felici A, Di Segni S, Micella M, et al. Pharmacokinetics
of gemcitabina at fixed-dose rate infusion in patients
with normal and impaired hepatic function. Clin Pharmacokinet
2009; 48: 131-41
Hamilton SR, Aaltonen LA (eds.). World Health Organization
Classification of Tumour. Pathology and
Genetics of Tumours of Endocrine Organs. Lyon:
IARC press, 2004
Heinemann V, Boeck S, Hinke A, Labianca R, Louvet
C. Meta-analysis of randomized trials: evaluation of
benefit from gemcitabine-based combination chemo -
therapy applied in advanced pancreatic cancer. BMC
Cancer 2008; 8: 82
Heinemann V, Labianca R, Hinke A, Louvet C. Increased
survival using platinum analog combined with
gemcitabine as compared to single-agent gemcitabine
in advanced pancreatic cancer: pooled analysis of two
randomized trials, the GERCOR/GISCAD intergroup
study and a German multicenter study. Ann Oncol
2007; 18: 1652-9
Hruban RH, Adsay NV. Molecular classification of
neoplasm of the pancreas. Human Pathology 2009;
40: 612-23
Krishna NB, Labundy JL, Saripalli S, et al. Diagnostic
value of EUS-FNA in patients suspected of having
pancreatic cancer with a focal lesion on CT scan/MRI
but without obstructive jaundice. Pancreas 2009; 38:
625-30
Melotti G, Butturini G, Piccoli M, et al. Laparoscopic
distal pancreatectomy: results on a consecutive series
of 58 patients. Ann Surg 2007; 246: 77-82
118